Posted by Michael Wonder on 24 Oct 2017
Top Celgene cancer drugs now 20% more expensive after latest price hikes
23 October 2017 - Blockbuster drugs Revlimid and Pomalyst are Celgene’s two most valuable products — now especially so.
Celgene has raised the prices of two top cancer drugs again, bringing price increases on the drugs to nearly 20% this year.
The hikes, which went into effect Thursday, were made on blockbuster drugs Revlimid and Pomalyst. Both treat the rare blood cancer multiple myeloma, while Revlimid is also approved for several other types of cancer, including another rare blood cancer, mantle cell lymphoma.
For Revlimid, it is the third such hike this year, bringing the therapy’s price to $18,546 per bottle; it is the second hike for Pomalyst this year, bringing the total price to $15,833 per bottle, according to SunTrust Robinson Humphrey analyst Yatin Suneja, who relied on data from information services company Wolters Kluwer. (The figures refer to the therapies’ wholesale acquisition price, or the price a drugmaker offers to middlemen wholesalers.)
